Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James C. Mullikin is active.

Publication


Featured researches published by James C. Mullikin.


Nature | 2002

The mosaic structure of variation in the laboratory mouse genome

Claire M. Wade; Edward J. Kulbokas; Andrew Kirby; Michael C. Zody; James C. Mullikin; Eric S. Lander; Kerstin Lindblad-Toh; Mark J. Daly

Most inbred laboratory mouse strains are known to have originated from a mixed but limited founder population in a few laboratories. However, the effect of this breeding history on patterns of genetic variation among these strains and the implications for their use are not well understood. Here we present an analysis of the fine structure of variation in the mouse genome, using single nucleotide polymorphisms (SNPs). When the recently assembled genome sequence from the C57BL/6J strain is aligned with sample sequence from other strains, we observe long segments of either extremely high (∼40 SNPs per 10 kb) or extremely low (∼0.5 SNPs per 10 kb) polymorphism rates. In all strain-to-strain comparisons examined, only one-third of the genome falls into long regions (averaging >1 Mb) of a high SNP rate, consistent with estimated divergence rates between Mus musculus domesticus and either M. m. musculus or M. m. castaneus. These data suggest that the genomes of these inbred strains are mosaics with the vast majority of segments derived from domesticus and musculus sources. These observations have important implications for the design and interpretation of positional cloning experiments.


Proceedings of the National Academy of Sciences of the United States of America | 2013

Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants

Stephen C. J. Parker; Michael L. Stitzel; D. Leland Taylor; Jose Miguel Orozco; Michael R. Erdos; Jennifer A. Akiyama; Kelly Lammerts van Bueren; Peter S. Chines; Nisc Comparative Sequencing Program; Brian L. Black; Axel Visel; Len A. Pennacchio; Francis S. Collins; Jesse Becker; Betty Benjamin; Robert W. Blakesley; Gerry Bouffard; Shelise Brooks; Holly Coleman; Mila Dekhtyar; Michael Gregory; Xiaobin Guan; Jyoti Gupta; Joel Han; April Hargrove; Shi-ling Ho; Taccara Johnson; Richelle Legaspi; Sean Lovett; Quino Maduro

Significance Using high-throughput experiments, we determined the functional epigenomic landscape in pancreatic islet cells. Computational integration of these data along with similar data from the ENCODE project revealed the presence of large gene control elements across diverse cell types that we refer to as “stretch enhancers.” Stretch enhancers are cell type specific and are associated with increased expression of genes involved in cell-specific processes. We find that genetic variations associated with common disease are highly enriched in stretch enhancers; notably, stretch enhancers specific to pancreatic islets harbor variants linked to type 2 diabetes and related traits. We propose that stretch enhancers form as pluripotent cells differentiate into committed lineages, to program important cell-specific gene expression. Chromatin-based functional genomic analyses and genomewide association studies (GWASs) together implicate enhancers as critical elements influencing gene expression and risk for common diseases. Here, we performed systematic chromatin and transcriptome profiling in human pancreatic islets. Integrated analysis of islet data with those from nine cell types identified specific and significant enrichment of type 2 diabetes and related quantitative trait GWAS variants in islet enhancers. Our integrated chromatin maps reveal that most enhancers are short (median = 0.8 kb). Each cell type also contains a substantial number of more extended (≥3 kb) enhancers. Interestingly, these stretch enhancers are often tissue-specific and overlap locus control regions, suggesting that they are important chromatin regulatory beacons. Indeed, we show that (i) tissue specificity of enhancers and nearby gene expression increase with enhancer length; (ii) neighborhoods containing stretch enhancers are enriched for important cell type–specific genes; and (iii) GWAS variants associated with traits relevant to a particular cell type are more enriched in stretch enhancers compared with short enhancers. Reporter constructs containing stretch enhancer sequences exhibited tissue-specific activity in cell culture experiments and in transgenic mice. These results suggest that stretch enhancers are critical chromatin elements for coordinating cell type–specific regulatory programs and that sequence variation in stretch enhancers affects risk of major common human diseases.


Nature Genetics | 2012

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes

Matthieu Le Gallo; Andrea J O'Hara; Meghan L. Rudd; Mary Ellen Urick; Nancy F. Hansen; Nigel J. O'Neil; Jessica C. Price; Suiyuan Zhang; Bryant M England; Andrew K. Godwin; Dennis C. Sgroi; Philip Hieter; James C. Mullikin; Maria J. Merino; Daphne W. Bell

Endometrial cancer is the sixth most commonly diagnosed cancer in women worldwide, causing ∼74,000 deaths annually. Serous endometrial cancers are a clinically aggressive subtype with a poorly defined genetic etiology. We used whole-exome sequencing to comprehensively search for somatic mutations within ∼22,000 protein-encoding genes in 13 primary serous endometrial tumors. We subsequently resequenced 18 genes, which were mutated in more than 1 tumor and/or were components of an enriched functional grouping, from 40 additional serous tumors. We identified high frequencies of somatic mutations in CHD4 (17%), EP300 (8%), ARID1A (6%), TSPYL2 (6%), FBXW7 (29%), SPOP (8%), MAP3K4 (6%) and ABCC9 (6%). Overall, 36.5% of serous tumors had a mutated chromatin-remodeling gene, and 35% had a mutated ubiquitin ligase complex gene, implicating frequent mutational disruption of these processes in the molecular pathogenesis of one of the deadliest forms of endometrial cancer.


Nature Genetics | 2007

Measurement of the human allele frequency spectrum demonstrates greater genetic drift in East Asians than in Europeans

Alon Keinan; James C. Mullikin; Nick Patterson; David Reich

Large data sets on human genetic variation have been collected recently, but their usefulness for learning about history and natural selection has been limited by biases in the ways polymorphisms were chosen. We report large subsets of SNPs from the International HapMap Project that allow us to overcome these biases and to provide accurate measurement of a quantity of crucial importance for understanding genetic variation: the allele frequency spectrum. Our analysis shows that East Asian and northern European ancestors shared the same population bottleneck expanding out of Africa but that both also experienced more recent genetic drift, which was greater in East Asians.


Genome Research | 2010

Systematic comparison of three genomic enrichment methods for massively parallel DNA sequencing

Jamie K. Teer; Lori L. Bonnycastle; Peter S. Chines; Nancy F. Hansen; Natsuyo Aoyama; Amy J. Swift; Hatice Ozel Abaan; Thomas J. Albert; Nisc Comparative Sequencing Program; Elliott H. Margulies; Eric D. Green; Francis S. Collins; James C. Mullikin; Leslie G. Biesecker

Massively parallel DNA sequencing technologies have greatly increased our ability to generate large amounts of sequencing data at a rapid pace. Several methods have been developed to enrich for genomic regions of interest for targeted sequencing. We have compared three of these methods: Molecular Inversion Probes (MIP), Solution Hybrid Selection (SHS), and Microarray-based Genomic Selection (MGS). Using HapMap DNA samples, we compared each of these methods with respect to their ability to capture an identical set of exons and evolutionarily conserved regions associated with 528 genes (2.61 Mb). For sequence analysis, we developed and used a novel Bayesian genotype-assigning algorithm, Most Probable Genotype (MPG). All three capture methods were effective, but sensitivities (percentage of targeted bases associated with high-quality genotypes) varied for an equivalent amount of pass-filtered sequence: for example, 70% (MIP), 84% (SHS), and 91% (MGS) for 400 Mb. In contrast, all methods yielded similar accuracies of >99.84% when compared to Infinium 1M SNP BeadChip-derived genotypes and >99.998% when compared to 30-fold coverage whole-genome shotgun sequencing data. We also observed a low false-positive rate with all three methods; of the heterozygous positions identified by each of the capture methods, >99.57% agreed with 1M SNP BeadChip, and >98.840% agreed with the whole-genome shotgun data. In addition, we successfully piloted the genomic enrichment of a set of 12 pooled samples via the MGS method using molecular bar codes. We find that these three genomic enrichment methods are highly accurate and practical, with sensitivities comparable to that of 30-fold coverage whole-genome shotgun data.


Cell Stem Cell | 2012

Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression.

Linzhao Cheng; Nancy F. Hansen; Ling Zhao; Yutao Du; Chunlin Zou; Frank X. Donovan; Bin Kuan Chou; Guangyu Zhou; Shijie Li; Sarah N. Dowey; Zhaohui Ye; Settara C. Chandrasekharappa; Huanming Yang; James C. Mullikin; P. Paul Liu

The utility of induced pluripotent stem cells (iPSCs) as models to study diseases and as sources for cell therapy depends on the integrity of their genomes. Despite recent publications of DNA sequence variations in the iPSCs, the true scope of such changes for the entire genome is not clear. Here we report the whole-genome sequencing of three human iPSC lines derived from two cell types of an adult donor by episomal vectors. The vector sequence was undetectable in the deeply sequenced iPSC lines. We identified 1,058-1,808 heterozygous single-nucleotide variants (SNVs), but no copy-number variants, in each iPSC line. Six to twelve of these SNVs were within coding regions in each iPSC line, but ~50% of them are synonymous changes and the remaining are not selectively enriched for known genes associated with cancers. Our data thus suggest that episome-mediated reprogramming is not inherently mutagenic during integration-free iPSC induction.


Genetics in Medicine | 2011

The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases

William A. Gahl; Thomas C. Markello; Camilo Toro; Karin Fuentes Fajardo; Murat Sincan; Fred Gill; Hannah Carlson-Donohoe; Andrea Gropman; Tyler Mark Pierson; Gretchen Golas; Lynne A. Wolfe; Catherine Groden; Rena Godfrey; Michele E. Nehrebecky; Colleen Wahl; Dennis M. D. Landis; Sandra Yang; Anne Madeo; James C. Mullikin; Cornelius F. Boerkoel; Cynthia J. Tifft; David Adams

Purpose:This report describes the National Institutes of Health Undiagnosed Diseases Program, details the Program’s application of genomic technology to establish diagnoses, and details the Program’s success rate during its first 2 years.Methods:Each accepted study participant was extensively phenotyped. A subset of participants and selected family members (29 patients and 78 unaffected family members) was subjected to an integrated set of genomic analyses including high-density single-nucleotide polymorphism arrays and whole exome or genome analysis.Results:Of 1,191 medical records reviewed, 326 patients were accepted and 160 were admitted directly to the National Institutes of Health Clinical Center on the Undiagnosed Diseases Program service. Of those, 47% were children, 55% were females, and 53% had neurologic disorders. Diagnoses were reached on 39 participants (24%) on clinical, biochemical, pathologic, or molecular grounds; 21 diagnoses involved rare or ultra-rare diseases. Three disorders were diagnosed based on single-nucleotide polymorphism array analysis and three others using whole exome sequencing and filtering of variants. Two new disorders were discovered. Analysis of the single-nucleotide polymorphism array study cohort revealed that large stretches of homozygosity were more common in affected participants relative to controls.Conclusion:The National Institutes of Health Undiagnosed Diseases Program addresses an unmet need, i.e., the diagnosis of patients with complex, multisystem disorders. It may serve as a model for the clinical application of emerging genomic technologies and is providing insights into the characteristics of diseases that remain undiagnosed after extensive clinical workup.Genet Med 2012:14(1):51–59


Nature | 2001

Cancer and Genomics

P. A. Futreal; A. Kasprzyk; Ewan Birney; James C. Mullikin; Richard Wooster; Michael R. Stratton

Identification of the genes that cause oncogenesis is a central aim of cancer research. We searched the proteins predicted from the draft human genome sequence for paralogues of known tumour suppressor genes, but no novel genes were identified. We then assessed whether it was possible to search directly for oncogenic sequence changes in cancer cells by comparing cancer genome sequences against the draft genome. Apparently chimaeric transcripts (from oncogenic fusion genes generated by chromosomal translocations, the ends of which mapped to different genomic locations) were detected to the same degree in both normal and neoplastic tissues, indicating a significant level of false positives. Our experiment underscores the limited amount and variable quality of DNA sequence from cancer cells that is currently available.


Nature | 2000

An SNP map of human chromosome 22.

James C. Mullikin; Sarah Hunt; Charlotte G. Cole; Beverley Mortimore; Catherine M. Rice; J. Burton; L. H. Matthews; R. Pavitt; R. W. Plumb; Sarah Sims; R. M. R. Ainscough; J. Attwood; J. M. Bailey; K. Barlow; R. M. M. Bruskiewich; P. N. Butcher; Nigel P. Carter; Yuan Chen; C. M. Clee; Penny Coggill; J. Davies; Robert Davies; E. Dawson; M. D. Francis; A. A. Joy; R. G. Lamble; Cordelia Langford; J. Macarthy; V. Mall; A. Moreland

The human genome sequence will provide a reference for measuring DNA sequence variation in human populations. Sequence variants are responsible for the genetic component of individuality, including complex characteristics such as disease susceptibility and drug response. Most sequence variants are single nucleotide polymorphisms (SNPs), where two alternate bases occur at one position. Comparison of any two genomes reveals around 1 SNP per kilobase. A sufficiently dense map of SNPs would allow the detection of sequence variants responsible for particular characteristics on the basis that they are associated with a specific SNP allele. Here we have evaluated large-scale sequencing approaches to obtaining SNPs, and have constructed a map of 2,730 SNPs on human chromosome 22. Most of the SNPs are within 25 kilobases of a transcribed exon, and are valuable for association studies. We have scaled up the process, detecting over 65,000 SNPs in the genome as part of The SNP Consortium programme, which is on target to build a map of 1 SNP every 5 kilobases that is integrated with the human genome sequence and that is freely available in the public domain.


Nature Genetics | 2016

Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease

Qing Zhou; Hongying Wang; Daniella M. Schwartz; Monique Stoffels; Yong Hwan Park; Yuan Zhang; Dan Yang; Erkan Demirkaya; Masaki Takeuchi; Wanxia Li Tsai; Jonathan J. Lyons; Xiaomin Yu; Claudia Ouyang; Celeste Chen; David T. Chin; Kristien Zaal; Settara C. Chandrasekharappa; Eric P. Hanson; Zhen Yu; James C. Mullikin; Sarfaraz Hasni; Ingrid E Wertz; Amanda K. Ombrello; Deborah L. Stone; Patrycja Hoffmann; Anne Jones; Beverly Barham; Helen L. Leavis; Annet van Royen-Kerkof; Cailin Sibley

Systemic autoinflammatory diseases are driven by abnormal activation of innate immunity. Herein we describe a new disease caused by high-penetrance heterozygous germline mutations in TNFAIP3, which encodes the NF-κB regulatory protein A20, in six unrelated families with early-onset systemic inflammation. The disorder resembles Behçets disease, which is typically considered a polygenic disorder with onset in early adulthood. A20 is a potent inhibitor of the NF-κB signaling pathway. Mutant, truncated A20 proteins are likely to act through haploinsufficiency because they do not exert a dominant-negative effect in overexpression experiments. Patient-derived cells show increased degradation of IκBα and nuclear translocation of the NF-κB p65 subunit together with increased expression of NF-κB–mediated proinflammatory cytokines. A20 restricts NF-κB signals via its deubiquitinase activity. In cells expressing mutant A20 protein, there is defective removal of Lys63-linked ubiquitin from TRAF6, NEMO and RIP1 after stimulation with tumor necrosis factor (TNF). NF-κB–dependent proinflammatory cytokines are potential therapeutic targets for the patients with this disease.

Collaboration


Dive into the James C. Mullikin's collaboration.

Top Co-Authors

Avatar

Nancy F. Hansen

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Pedro Cruz

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Praveen F. Cherukuri

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Alice C. Young

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

William A. Gahl

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Baishali Maskeri

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Gerard G. Bouffard

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Robert W. Blakesley

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cynthia J. Tifft

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge